Daniel E. Furst, Robert Wallis MD, Michael Broder MD and David O. Beenhouwer MD. Tumor Necrosis Factor Antagonists: Different Kinetics and/or Mechanisms of Action May Explain Differences in the Risk for Developing Granulomatous Infection.
Seminars in Arthritis and Rheumatism 2006;36,3: 159-167
(PubMed)
Catrina AI, AF Klint, Ernestam S, Catrina SB, Makrygiannakis D, Botusan IR, Klareskog L, Ulfgren AK.
Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
Arthritis Rheum. 2006 Jan;54(1):76-81.
(PubMed)
Yim DS, Zhou H, Buckwalter M, Nestorov I, Peck CC, Lee H.
Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis.
J Clin Pharmacol. 2005 Mar;45(3):246-56.
(PubMed)
Catrina AI, Trollmo C, af Klint E, Engstrom M, Lampa J, Hermansson Y, Klareskog L, Ulfgren AK.
Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report.
Arthritis Rheum. 2005 Jan;52(1):61-72.
(PubMed)
Zhou H
Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein
J Clin Pharmacol. 2005 May;45(5):490-7
(PubMed)
Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J.
Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept.
Ann Rheum Dis. 2003; 62(6):561-4
(PubMed)
Catrina AI, Lampa J, Ernestam S, af Klint E, Bratt J, Klareskog L, Ulfgren AK.
Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis.
Rheumatology (Oxford). 2002 May;41(5):484-9.
(PubMed)
Korth-Bradley JM, Rubin AS, Hanna RK, Simcoe DK, Lebsack ME.
The pharmacokinetics of etanercept in healthy volunteers.
Ann Pharmacother. 2000 Feb;34(2):161-4.
(PubMed)
rheuma-online: TNF-alpha-Blocker: Alle gleich? Oder gibt es Unterschiede?
Druckversion
